Cargando…

Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery

INTRODUCTION: The standard of care for reversal of opioid-induced respiratory depression associated with opioid overdose is injectable naloxone. This study compared the usability of two naloxone delivery devices, a naloxone auto-injector (NAI) and a naloxone intranasal delivery system (NXN), in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Evan T., Edwards, Eric S., Davis, Erin, Mulcare, Maureen, Wiklund, Michael, Kelley, Glen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470965/
https://www.ncbi.nlm.nih.gov/pubmed/25910473
http://dx.doi.org/10.1007/s40122-015-0035-9
_version_ 1782376826657570816
author Edwards, Evan T.
Edwards, Eric S.
Davis, Erin
Mulcare, Maureen
Wiklund, Michael
Kelley, Glen
author_facet Edwards, Evan T.
Edwards, Eric S.
Davis, Erin
Mulcare, Maureen
Wiklund, Michael
Kelley, Glen
author_sort Edwards, Evan T.
collection PubMed
description INTRODUCTION: The standard of care for reversal of opioid-induced respiratory depression associated with opioid overdose is injectable naloxone. This study compared the usability of two naloxone delivery devices, a naloxone auto-injector (NAI) and a naloxone intranasal delivery system (NXN), in the administration of naloxone during a simulated opioid overdose emergency. NAI (EVZIO(®); kaleo, Inc., Richmond, VA, USA) is a Food and Drug Administration approved single-use pre-filled auto-injector containing 0.4 mg of naloxone. METHODS: Study participants were randomly assigned to administer naloxone using NAI and NXN, sequentially. The primary endpoint was successful administration of a simulated dose of naloxone into a mannequin during a simulated opioid emergency, both before and after receiving training. Secondary endpoints included using the NAI or NXN in accordance with the instructions-for-use and the comparative measurement of successful completion time of administration for both NAI and NXN. RESULTS: A total of 42 healthy participants aged 18–65 years were enrolled in the study. The proportion of participants able to successfully administer a simulated dose of naloxone was significantly greater for NAI compared to NXN both before (90.5% vs. 0.0%, respectively, P < 0.0001) and after (100% vs. 57.1%, respectively, P < 0.0001) participant training. The proportion of participants able to administer a simulated dose of naloxone in accordance with the instructions-for-use was also significantly greater for NAI compared to NXN before (85.7% vs. 0.0%, respectively, P < 0.0001) and after (100% vs. 0.0%, respectively, P < 0.0001) participant training. The average time to task completion for administration attempt before training was 0.9 ± 0.25 min for NAI versus 6.0 ± 4.76 min for NXN and after training was 0.5 ± 0.15 min for NAI versus 2.0 ± 2.15 min for NXN. CONCLUSION: Laypersons experienced substantially greater success administering a simulated dose of naloxone, both before and after training, using NAI versus NXN during a simulated opioid overdose emergency. No participants correctly used NXN without training. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40122-015-0035-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4470965
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-44709652015-06-18 Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery Edwards, Evan T. Edwards, Eric S. Davis, Erin Mulcare, Maureen Wiklund, Michael Kelley, Glen Pain Ther Original Research INTRODUCTION: The standard of care for reversal of opioid-induced respiratory depression associated with opioid overdose is injectable naloxone. This study compared the usability of two naloxone delivery devices, a naloxone auto-injector (NAI) and a naloxone intranasal delivery system (NXN), in the administration of naloxone during a simulated opioid overdose emergency. NAI (EVZIO(®); kaleo, Inc., Richmond, VA, USA) is a Food and Drug Administration approved single-use pre-filled auto-injector containing 0.4 mg of naloxone. METHODS: Study participants were randomly assigned to administer naloxone using NAI and NXN, sequentially. The primary endpoint was successful administration of a simulated dose of naloxone into a mannequin during a simulated opioid emergency, both before and after receiving training. Secondary endpoints included using the NAI or NXN in accordance with the instructions-for-use and the comparative measurement of successful completion time of administration for both NAI and NXN. RESULTS: A total of 42 healthy participants aged 18–65 years were enrolled in the study. The proportion of participants able to successfully administer a simulated dose of naloxone was significantly greater for NAI compared to NXN both before (90.5% vs. 0.0%, respectively, P < 0.0001) and after (100% vs. 57.1%, respectively, P < 0.0001) participant training. The proportion of participants able to administer a simulated dose of naloxone in accordance with the instructions-for-use was also significantly greater for NAI compared to NXN before (85.7% vs. 0.0%, respectively, P < 0.0001) and after (100% vs. 0.0%, respectively, P < 0.0001) participant training. The average time to task completion for administration attempt before training was 0.9 ± 0.25 min for NAI versus 6.0 ± 4.76 min for NXN and after training was 0.5 ± 0.15 min for NAI versus 2.0 ± 2.15 min for NXN. CONCLUSION: Laypersons experienced substantially greater success administering a simulated dose of naloxone, both before and after training, using NAI versus NXN during a simulated opioid overdose emergency. No participants correctly used NXN without training. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40122-015-0035-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-04-25 2015-06 /pmc/articles/PMC4470965/ /pubmed/25910473 http://dx.doi.org/10.1007/s40122-015-0035-9 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Edwards, Evan T.
Edwards, Eric S.
Davis, Erin
Mulcare, Maureen
Wiklund, Michael
Kelley, Glen
Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title_full Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title_fullStr Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title_full_unstemmed Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title_short Comparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
title_sort comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470965/
https://www.ncbi.nlm.nih.gov/pubmed/25910473
http://dx.doi.org/10.1007/s40122-015-0035-9
work_keys_str_mv AT edwardsevant comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery
AT edwardserics comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery
AT daviserin comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery
AT mulcaremaureen comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery
AT wiklundmichael comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery
AT kelleyglen comparativeusabilitystudyofanovelautoinjectorandanintranasalsystemfornaloxonedelivery